Vaccitech, startup behind Oxford Covid vaccine tech, falls 20% in Nasdaq debut
American depositary shares of Vaccitech fell nearly 20% in their Nasdaq debut on Friday, giving the co-inventor of the Covid-19 vaccine developed by AstraZeneca Plc and Oxford University a market value of about $464 million. The biotech firm’s shares opened at $13.62, below the initial public offering (IPO) price of $17 apiece for 6.5 million … Read more